Status:
COMPLETED
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Lead Sponsor:
Escient Pharmaceuticals, Inc
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Eligibility Criteria
Inclusion
- Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
- BSA of 3% to 20% and a vIGA-AD score of ≥3
Exclusion
- Other active skin diseases associated with chronic pruritus
- Clinically infected atopic dermatitis that requires antibiotic therapy
- Use of specific treatments for atopic dermatitis
Key Trial Info
Start Date :
October 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06144424
Start Date
October 25 2023
End Date
July 31 2024
Last Update
August 24 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Allervie Clinical Research
Birmingham, Alabama, United States, 35209
2
RM Medical Research, Inc.
Miami Lakes, Florida, United States, 33014
3
Indiana Clinical Trials Center
Plainfield, Indiana, United States, 46168
4
Lawrence J. Green, MD LLC
Rockville, Maryland, United States, 20850